The Promise and Challenge of In Vivo Delivery for Genome Therapeutics.
The Promise and Challenge of In Vivo Delivery for Genome Therapeutics.
复制标题
DOI:
10.1021/acschembio.7b00680
复制
发表时间:
2018-02-16
影响因子:
4
通讯作者:
Gilbert LA
中科院分区:
文献类型:
--
作者:
Wilson RC;Gilbert LA
CRISPR-based genome editing technologies are poised to enable countless new therapies to prevent, treat or cure diseases with a genetic basis. However, the safe and effective delivery of genome editing enzymes represents a substantial challenge that must be tackled to enable the next generation of genetic therapies. In this perspective we summarize recent progress in developing enzymatic tools to combat genetic disease and examine current efforts to deliver these enzymes to the cells in need of correction. Viral vectors already in use for traditional gene therapy are being applied to enable in vivo CRISPR-based therapeutics, as are emerging technologies such as nanoparticle-based delivery of CRISPR components and direct delivery of pre-assembled RNA-protein complexes. Success in these areas will allow CRISPR-based genome editing therapeutics to reach their full potential.
登录
查看更多内容
影响因子:
14.9
作者:
Gaj T;Staahl BT;Rodrigues GMC;Limsirichai P;Ekman FK;Doudna JA;Schaffer DV
通讯作者:
Schaffer DV
影响因子:
4.2
作者:
Kattenhorn LM;Tipper CH;Stoica L;Geraghty DS;Wright TL;Clark KR;Wadsworth SC
通讯作者:
Wadsworth SC
DOI:
10.1007/s11481-016-9724-3
发表时间:
2017-03
期刊:
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
影响因子:
--
作者:
Joshi CR;Labhasetwar V;Ghorpade A
通讯作者:
Ghorpade A
DOI:
10.1111/cts.12466
发表时间:
2017-07
期刊:
Clinical and translational science
影响因子:
--
作者:
Keeler AM;ElMallah MK;Flotte TR
通讯作者:
Flotte TR
影响因子:
64.8
作者:
Eyquem J;Mansilla-Soto J;Giavridis T;van der Stegen SJ;Hamieh M;Cunanan KM;Odak A;Gönen M;Sadelain M
通讯作者:
Sadelain M